Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards on March 26, 2026 to two new employees under its 2015 New Employee Incentive Plan.
The awards total 300,000 stock options (10-year term, $0.243 exercise price) and 300,000 RSUs. Options vest over four years; RSUs vest over three years.
Positive
- None.
Negative
- None.
News Market Reaction – PSTV
On the day this news was published, PSTV declined 4.18%, reflecting a moderate negative market reaction. Argus tracked a trough of -35.0% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $36.81M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PSTV fell 6.7% while momentum peers were mixed: BCAB down 18.94%, GRCE down 1.94%, and RNXT up 3.95%. With two peers moving down, PSTV’s weakness fits into a broader, though uneven, biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Board appointment | Positive | -1.2% | Veteran diagnostics executive Ron Andrews added to Board for CNSide scaling. |
| Mar 19 | Health economics data | Positive | +2.2% | ISPOR analysis suggesting CNSide may cut LM healthcare costs by ~40%. |
| Mar 12 | Earnings and outlook | Neutral | -15.2% | 2025 results with cash of $13.1M and 2026 milestones for REYOBIQ and CNSide. |
| Feb 25 | New CPT code | Positive | +7.6% | Category III CPT code X566T approved for REYOBIQ convection-enhanced delivery. |
| Jan 22 | Business update | Neutral | -2.3% | Business update plus upsized $15M offering to fund REYOBIQ and CNSide goals. |
Across recent announcements, PSTV’s price has generally moved in the same direction as the qualitative tone of news, with one notable divergence on a positive board appointment.
Over the last few months, Plus Therapeutics has highlighted progress across REYOBIQ™ and CNSide®, including business updates, a new CPT code, and a health economics analysis suggesting CNSide could cut LM costs by ~40%. It also completed an upsized $15 million offering and reported 2025 results with increased cash to $13.1 million. Today’s inducement awards follow a March 26 board appointment, continuing a pattern of governance and compensation actions alongside clinical and commercial execution.
Market Pulse Summary
This announcement details standard inducement equity awards—300,000 options at an exercise price of $0.243 and 300,000 RSUs—granted under Nasdaq Listing Rule 5635(c)(4) to new employees. It follows recent governance, compensation, and clinical/commercial milestones for REYOBIQ™ and CNSide®. Investors tracking dilution and incentives may focus on how such grants fit within total share-based compensation, overall share count from recent filings, and the company’s ability to advance its CNS oncology programs toward the 2026–2027 milestones previously outlined.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
exercise price financial
fair market value financial
vesting financial
AI-generated analysis. Not financial advice.
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company.
The awards were granted on March 26, 2026 under the Company’s 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist in the aggregate of options to purchase 300,000 shares of Company common stock and 300,000 restricted stock units (“RSUs”).
The options have a 10-year term and an exercise price equal to
Each RSU represents a contingent right to receive one share of the Company’s common stock and there is no exercise price associated with the RSUs granted thereunder. The RSUs vest over a three-year period, with 1/3 vesting on the first anniversary of the grant date, and the remaining RSUs vesting ratably over the next 8 quarters, subject to the employee’s continued service with the Company through each applicable vesting date.
The awards were approved by the Compensation Committee of the Company’s board of directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Rule 5635(c)(4).
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as the CNSide® Tumor Cell Enumeration assay, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products.
Investor Contact
CORE IR
investor@plustherapeutics.com
